BAY-876 is the first highly selective GLUT1 inhibitor that increases esophageal squamous cell carcinoma (ESCC) cell sensitivity to cisplatin [51,52]. This evidence concerns the gene SLC2A1 and esophageal squamous cell carcinoma.